The FDA has approved a humanized monoclonal antibody to prevent chronic migraine headaches in adults.
Marketed as Ajovy, fremanezumab-vfrm binds to calcitonin gene-related peptide ligand and blocks it from binding to its receptor. The drug is administered by injection, either monthly or quarterly. Its ability to prevent migraine headaches was evaluated in 2 phase 3 clinical trials. In both trials, patients could use acute headache remedies and a subset in each study was allowed to use another preventive medication.
Voelker R. Preventive Migraine Drug Approved. JAMA. 2018;320(17):1746. doi:10.1001/jama.2018.16485
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: